Jump to main content
US EPA
United States Environmental Protection Agency
Search
Search
Main menu
Environmental Topics
Laws & Regulations
About EPA
Health & Environmental Research Online (HERO)
Contact Us
Print
Feedback
Export to File
Search:
This record has one attached file:
Add More Files
Attach File(s):
Display Name for File*:
Save
Citation
Tags
HERO ID
2347171
Reference Type
Journal Article
Title
In vitro and in vivo evaluations of a novel pulsed and controlled osmotic pump capsule
Author(s)
Zhang, W; Zhang, L; Qu, X; Zhu, Z; Pan, Y; Guan, J; Pan, W
Year
2015
Is Peer Reviewed?
Yes
Journal
Drug Development and Industrial Pharmacy
ISSN:
0363-9045
EISSN:
1520-5762
Publisher
Informa Healthcare
Volume
41
Issue
2
Page Numbers
322-332
Language
English
PMID
24295490
DOI
10.3109/03639045.2013.859265
Web of Science Id
WOS:000348923200020
Abstract
Abstract Objective: For better treatment of circadian cardiovascular events, a novel Propranolol hydrochloride (PNH) delayed-release osmotic pump capsule was developed. Methods: The capsule body was designed of asymmetric membrane and the capsule cap was made impermeable. The physical characteristics of capsule body walls and membrane permeability were compared among different coating solutions. Results: The formulation with the glycerin and diethyl phthalate (DEP) ratio of 5:4 appeared to be the best. The lag time and subsequent drug release were investigated through assembling the capsule body with capsule caps of different length. WSR N-10 was chosen as the suspending for its moderate expanding capacity. The influence of factors (WSR N-10 content, NaCl content and capsule cap length) on the responses (lag time and drug release rate) was evaluated using central composite design-response surface methodology. A second-order polynomial equation was fitted to the data and actual response values were in good accordance with the predicted ones. The optimized formulation displayed complete drug delivery, zero-order release rate with 4-h lag time. The results of in vivo pharmacokinetics in beagle dogs clearly suggested the controlled and sustained release of PNH from the system and that the relative bioavailability of this preparation was about 1.023 comparing the marketed preparation. Conclusions: These results indicate that by the adjustment of capsule cap length, PNH could be developed as a novel pulsatile and controlled drug delivery system.
Keywords
Central composite design; controlled release; delayed-release; osmotic pump capsule; pharmacokinetics
Tags
IRIS
•
Diethyl phthalate (DEP)
Database searches
Jul 2014 update
Pubmed
Feb 2015 update
Pubmed
Jun 2015 update
Web of Science
Jan 2016 update
Web of Science
Jun 2016 update
Web of Science
Jan 2020 update
PubMed
Web of Science
Excluded: No Primary Data on Health Effects
Manufacture/Use
Home
Learn about HERO
Using HERO
Search HERO
Projects in HERO
Risk Assessment
Transparency & Integrity